Sector News

Mylan says Teva’s stake buy violates U.S. anti-trust rules

June 2, 2015
Life sciences
(Reuters) – Mylan NV said Teva Pharmaceutical Industries Ltd , which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.
 
Teva disclosed a 1.35 percent stake in Mylan last week.
 
“We consider Teva’s stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions,” Mylan said in a letter addressed to Teva’s chief executive, Erez Vigodman.(http://1.usa.gov/1Q0SxgC)
 
Mylan did not clarify which anti-trust rule Teva violated.
 
The two companies were not immediately available for comment.
 
Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva’s offer for about $40 billion.
 
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend